New leukemia drug candidate undergoes heart safety check

NCT ID NCT07162116

Recruiting now Knowledge-focused Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing whether a single dose of XY0206 tablets affects the heart's electrical activity (QTc interval) in 45 healthy Chinese adults. Participants are randomly assigned to receive XY0206, a placebo, or an active control (moxifloxacin). The study lasts 3 days and monitors heart rhythm, drug levels in blood, and vital signs. It does not test the drug's ability to treat leukemia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XY0206 tablets
What this could lead to: If successful, this study will show whether XY0206 is safe for the heart, supporting further testing in people with leukemia.
What could go wrong: This is an early Phase 1 safety study in healthy volunteers, not patients. It cannot prove the drug works against leukemia, and heart effects may still appear later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia, FLT3 internal tandem duplication

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION

Contacts and locations

Locations

PKUCare Luzhong Hospital
RECRUITING

Zibo, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.